Rituximab Transplant denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab transplant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Rituximab (Transplant) as Not FDA-Approved

Blue Cross Blue Shield plans sometimes issue "not FDA-approved" denials for rituximab in transplant indications because several transplant uses — including desensitization prior to transplant, treatment of antibody-mediated rejection, and certain post-transplant complications — are used in clinical practice but are not among rituximab's original FDA-labeled indications. This is commonly called "off-label" use. BCBS may cite its off-label use policy and deny coverage when the request does not satisfy the plan's specific criteria for recognizing evidence-based off-label treatments.

This denial is routinely overturned on appeal when the off-label use is supported by recognized medical compendia or major transplant society guidelines — which is typically the case for rituximab in transplant medicine.

## Your Appeal Rights

Federal law does not prohibit insurers from covering off-label drug use, and many state laws and ERISA guidance affirmatively require coverage when the use is supported by recognized medical compendia. Under ACA Section 2719, you have the right to internal appeal and independent external review. Under ERISA Section 503, employer-sponsored plans must provide full-and-fair review. File an internal appeal within 180 days of denial. If denied internally, pursue external review within four months. Expedited review is available for urgent clinical situations.

## Building a Strong Off-Label Appeal

The central task is demonstrating that the use is supported by authoritative medical literature and recognized by major transplant medicine organizations — even if it predates formal FDA label expansion.

Documentation to assemble: - Prescriber letter that specifically addresses the off-label status, explains the clinical evidence base, and references recognized transplant society guidelines by organization name - Evidence that the use appears in a recognized medical compendia (BCBS policies often enumerate accepted compendia — request their off-label use policy by name) - Diagnosis and transplant history establishing why this use is appropriate for this patient - Any relevant BCBS off-label coverage policy: request it in writing, then map each criterion to chart evidence

## Criteria-Mapping Structure

Obtain BCBS's off-label use coverage policy. Most such policies list approved compendia and require the prescriber to certify the use is supported by a specific compendia entry or published clinical evidence. For each requirement: - Policy requires: [copy the exact criterion verbatim] - Documentation shows: [cite the specific record, letter, or reference that satisfies it]

Also review the FDA prescribing label for rituximab — the label's safety and pharmacology information remains authoritative even for off-label discussions. Note any language in the label that is consistent with the transplant use being requested.